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Abstract 
Cancer therapies will increasingly be utilized in combination to treat advanced malignancies 
so as to increase their long-term efficacy in a greater proportion of patients.  In particular, 
much attention has focused on developing targeted therapies that inhibit the PI3K-AKT-
mTOR signaling network which is dysregulated in many cancer types. In addition, there is 
now a growing appreciation that targeting of these pathways can impact not only on cancer 
cells, but also host immunity. The clinical success of cancer immunotherapies targeting T-cell 
immune checkpoint receptors PD-1/PD-L1 has demonstrated the importance of 
immunoevasion as a hallmark of cancer. In this review, we discuss how PI3K-AKT-mTOR 
inhibitors target cancer cell biology, attenuate immune cell effector function and modulate 
the tumor microenvironment. We next discuss how the immunomodulatory potential of these 
inhibitors can be exploited through rational combinations with immunotherapies and targeted 
therapies. 
 
Keywords: PI3K, AKT, mTOR, inhibitions, targeted therapy, immunotherapy, combination 
therapy, tumor microenvironment, immunotherapeutic resistance.  
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Introduction  
In the past five years, cancer immunotherapy has achieved remarkable clinical efficacy in the 
treatment of many advanced cancer types [1]. This success represents the culmination of two 
decades of key research studies and conceptual developments that have occurred in the 
cancer immunology field. In particular, it is now appreciated that an immune response against 
tumor-specific neoantigens can be generated but the efficacy of these tumor-specific T cells 
can be limited by the immunosuppressive microenvironment fostered by many tumors [1, 2]. 
To date, therapies that relieve T cell suppression such as monoclonal antibodies targeting 
cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein 1 
(PD-1) receptor expressed on T cells or its primary ligand programmed cell death ligand 1 
(PD-L1) expressed on tumors or immune cells, have demonstrated the greatest clinical 
benefit [3-5]. In addition, a further increase in clinical efficacy was obtained by co-targeting 
CTLA-4 and PD-1 in the treatment of advanced melanoma [6, 7], demonstrating multiple 
non-redundant immunosuppressive pathways exist in the tumor microenvironment (TME). 
Nevertheless, only 50% of patients responded to anti-CTLA-4 and anti-PD-1 combination 
treatment, and treatment is in some cases associated with severe toxicity [8]. Although single 
agent anti-PD-1/PD-L1 therapy have demonstrated promising clinical activity in diverse 
tumor types including melanoma, renal cell carcinoma and lung cancer, there are still a 
significant proportion of patients who display primary resistance to these therapies [5].  More 
recently, a proportion of melanoma patients who previously were responsive to anti-PD-1 
relapsed, demonstrating that like targeted therapies, acquired resistance to immunotherapies 
can develop [9]. Thus, identifying strategies to further increase the efficacy of cancer 
immunotherapies in a wider proportion of cancer patients is a key research focus. Given the 
safety profile of agents targeting the PD-1/PD-L1 pathway [3, 5, 10], these agents are 
currently being evaluated in combination with other therapies such as targeted therapies.  
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The signaling network defined by the phosphoinositide 3-kinase (PI3K), AKT (also referred 
to as protein kinase B (PKB) [11]) and mammalian target of rapamycin (mTOR), controls 
most hallmarks of cancer including cell cycle, survival, metabolism, motility and genomic 
instability; it was this understanding that prompted the development of therapeutic reagents to 
inhibit this pathway in oncology [12]. It is becoming increasingly apparent that this network 
also regulates many features of the immunosuppressive microenvironment. Interestingly, 
recent data derived from clinical trials and pre-clinical mouse models suggests that 
therapeutic inhibition of the PI3K-AKT-mTOR signaling network may have the dual benefit 
of staving tumor progression by limiting proliferation, migration and survival, and also 
augmenting tumor immunosurveillance by preventing activation of immunosuppressive 
pathways and enhancing anti-tumor immune-intrinsic properties [13]. While targeted 
therapies can induce high initial response rates, most patients relapse due to acquired 
resistance [14]. In this review, we first discuss how PI3K-AKT-mTOR inhibitors not only 
impact directly upon cancer cells, but also have the capacity to affect immune cell effector 
function and to modulate the tumor microenvironment. We next discuss how PI3K-AKT-
mTOR inhibitors can be rationally used in combination with immunotherapies and targeted 
therapies to improve outcomes for patients with a variety of cancers.  
 
PI3K-AKT-mTOR dysregulation in cancer  
Over the past 30 years, the PI3K-AKT-mTOR signaling pathway has been robustly 
characterized. Much is now understood regarding the molecular mechanisms by which this 
network regulates the activities of the cell cycle, cellular proliferation, growth, survival, 
protein synthesis and glucose metabolism [15, 16]. Schematically, growth factors, cytokines 
or chemokines can stimulate the activation of receptor tyrosine kinases (RTK). This allows 
for the down-stream activation of important signaling intermediates capable of activating 
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PI3K molecules. These kinases catalyse the conversion of phosphatidylinositol-4,5-
bisphosphate (PIP2) into phosphatidylinositol-3,4,5-trisphosphate (PIP3) [17]. These lipid 
products are capable of recruiting pleckstrin homology (PH) domain-containing proteins such 
as AKT, mTOR complex 2 (mTORC2), and phosphoinositide-dependent kinase 1 (PDK1); 
the interaction of either PDK1 or mTORC2 with AKT can trigger its activation [11, 18]. 
Finally, AKT activates the mTOR complex 1 (mTORC1) [19], which promotes cell growth 
and protein synthesis (Figure 1) [20, 21].  
 
Consistent with its physiological role, the PI3K-AKT-mTOR pathway has been found to be 
hyperactivated in many types of cancer. Overall, this pathway is dysregulated via several 
genetic mechanisms in approximately 30% of solid cancers (Table 1). As such, this 
represents one of the most frequently dysregulated signaling cascades in human cancers [12]. 
Oncogenic activation of the PI3K pathway can occur though several mechanisms such as, 
mutation and/or amplification of genes encoding RTKs [e.g., EGFR (ERBB1) and Her2 
(ERBB2)], subunits of the PI3K (e.g., p110α, p110β, p85α, and p85β), AKT (AKT1), or 
activating isoforms of the RAS GTPases [22-24]. Additionally, components of the PI3K 
pathway that negatively regulate its function such as the phosphate and tensin homologue 
(PTEN) are amongst the most frequently occurring tumor suppressor mutations in human 
cancers [25-27].  
 
Direct effects of PI3K-AKT-mTOR inhibitors on cancer cells  
In oncology, targeting of the PI3K-AKT-mTOR pathway was seen as an opportunity to 
overcome tumor complexity and genomic heterogeneity through a central oncogenic driver, 
essential to many cancers [28]. To date, there are six classes of compounds targeting the 
PI3K-AKT-mTOR pathway at different regulatory levels. These include mTOR inhibitors, 
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active site mTOR inhibitors, pan-class I PI3K inhibitors (PI3Ki), isoform-selective PI3Ki, 
pan-PI3K-mTOR inhibitors and AKT inhibitors (Table 2). These agents are currently being 
tested within clinical trials at different stages (Table 3) [29].  
 
Rapamycin and its analogues (rapalogues) are recognized as the first generation of mTOR 
inhibitors which inhibit the activity of mTORC1 by binding to FRBP-12 (12 kDa FK506-
binding protein; also known as FKBP1A), to form a ternary complex with mTOR [30, 31]. 
Rapalogues such as everolimus, temsirolimus, deforolimus, and ridaforolimus are currently 
undergoing a number of clinical trials for therapeutic efficacy in a variety of human 
malignancies [30]. To date, temsirolimus and everolimus have been FDA approved for the 
treatment of advanced renal cell carcinoma, subependymal giant cell astrocytoma and for 
progressive neuroendocrine tumors of pancreatic origin; however, only modest therapeutic 
effects have been observed [32, 33].  
 
Several pan-class I PI3K inhibitors target all four class I PI3K isoforms (PI3Kα, PI3Kβ, 
PI3Kγ and PI3Kδ) with similar potencies such as CDC-0941 [34], BKM120 [35], XL147 
[36], PX-866 [37], BAY806946 [38], and CH5132799 [39]; however, all remain within 
clinical trials. The primary argument in support of this modality is that most cancer cells 
express multiple PI3K isoforms with redundant functions [40]. The main concern associated 
with their use, is that doses needed to fully block all class I PI3Ks for extended periods might 
not be well-tolerated. For example, at the concentration needed to fully inhibit PI3K using the 
pan-PI3K inhibitor, BKM120 (buparsilib), off-target effects upon tubulin, resulting in cellular 
toxicity are observed [35]. For this reason, isoform-selective PI3K inhibitors with the 
capacity to completely block their relevant target, while limiting toxicities associated with the 
use of more broad inhibition have been developed [12]. Of these, the most impressive results 
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have been achieved using the p110δ-selective inhibitor, GS-1101 (idelalisib), which causes 
dramatic responses in chronic lymphocytic leukaemia, without any major off-target effects. 
As such GS-1101 has been approved as a first-in-class agent for the treatment of relapsed 
chronic lymphocytic leukaemia, follicular B cell non-Hodgkin’s lymphoma and small 
lymphocytic lymphoma [41, 42].  
 
As one of the key effector nodes in the PI3K pathway, AKT was also seen as an attractive 
therapeutic target. To date, two classes of pan-AKT inhibitors have been developed: i) 
allosteric inhibitors (e.g. MK-2206) which bind to the PH domain and prevent plasma 
membrane localisation, and phosphorylation at Thr308 and Ser473 by PDK1 and mTORC2, 
respectively; ii) adenosine triphosphate (ATP)-competitive inhibitors (e.g. AZD5363 [43], 
ipatasertib [GHC-0068] [44], afuresertib [45], and GSK2141795 [46]) which limit AKT 
kinase activity.  Early phase, single-agent clinical trials with AKT inhibitors have generally 
shown underwhelming efficacy, as having anti-proliferative, rather than antitumor activity, 
with stable disease identified as the best overall response [27, 47]. 
 
Overall, few PI3K-ATK-mTOR pathway inhibitors including small molecule inhibitors and 
biological reagents have reached later phases of drug development and approval. This is due 
to a few conceptual concerns which have hindered developmental progress such as: i) the 
challenge of targeting enzymes utilized by tumors that are also active, and play crucial roles 
in the homeostasis of most tissues; ii) pathway blockade generally fails to induce cancer cell 
death and can lead to selection of compensatory pathways that maintain survival which can 
eventually restore tumor growth; iii) oncogene addition to PI3K-AKT-mTOR signaling is not 
absolute; iv) the delivery of suboptimal dosing schedules due to toxicity; v) the presence of 
compensatory pathways, such as growth factor receptor signaling, which is capable of 
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bypassing the effects of targeted blockade. In any case, a large number of clinical trials are 
ongoing evaluating PI3K-AKT-mTOR inhibitors as monotherapies or in combination with 
other agents in (Table 3). Further investigation will almost certainly be needed to determine 
the mechanisms of actions of these therapies, and more specifically, to investigate their 
immunomodulatory effects within the tumour microenvironment in order to critically plan 
biomarker-enriched clinical trials.   
 
Effects of PI3K-AKT-mTOR inhibitors on the tumor microenvironment  
While the therapeutic effects of PI3K-AKT-mTOR inhibition are generally underwhelming, a 
body of recent research suggests that they can have significant biological effects in 
modulating both sides of the tumor-immune interface. Inflammation, while positive in some 
context, is a critical component of tumor progression [48]. The tumor microenvironment 
contains a variety of immune cell types which can either promote or limit tumor development 
and progression [49]. Interestingly, the activity of most immune cell types is at least, to some 
extent, affected by the PI3K-AKT-mTOR pathway [50]. As such, the PI3K-AKT-mTOR 
pathway can regulate tumor-intrinsic and immune-intrinsic features of the 
immunosuppressive tumor microenvironment. For example, PTEN-mutations within mouse 
models of melanoma have been shown separately to promote the expression of 
immunosuppressive cytokines and chemokines such as CCL20, CXCL1, IL6 and IL-23 [51], 
IL-6 and IL-10 [52], and also angiogenic factors such as VEGF [53]. Encouragingly, 
inhibition of the PI3K pathway using the selective PI3Kβ (p110β) isoform  inhibitor, 
GSK2636771 [53], or the pan-PI3K inhibitor, LY29002 [54] in various pre-clinical tumor 
models, has been shown to enhance CD8
+
 T cell infiltration within tumor tissue, resulting in 
reduced tumor burden and significant survival benefit [53, 54]. As well as promoting tumor 
vascularization, VEGF is important for promoting the infiltration of regulatory immune cell 
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subsets including immature dendritic cells, myeloid-derived suppressor cells (MDSCs), and 
regulatory T cells (Tregs); each capable of inhibiting functional anti-tumor immune responses 
[55, 56]. Therefore inhibition of VEGF secretion would likely promote anti-tumor immune 
responses.  
 
Additional immunosuppressive microenvironment features in the tumor such as expression of 
immune checkpoint ligands appear to be regulated by the PI3K-AKT-mTOR pathway under 
certain circumstances. A variety of human and mouse tumors lacking expression of the tumor 
suppressor gene PTEN, have been shown to over-express PD-L1 [57-60]. Although usually 
induced in response to inflammatory cytokines such as T cell-derived interferons (IFNs) [61], 
PD-L1 can also be regulated (at least at the post-transcriptional level) by the PI3K-AKT-
mTOR pathway [57]. The interaction of PD-L1 with PD-1 expressed by tumor-specific T 
cells can induce a state of functional exhaustion in which T cell proliferation, cytokine 
production, and migration are significantly limited [62]. This might provide one explanation 
as to why PTEN-mutant tumors are often veritable CD8
+
 T cell deserts, and why in turn, such 
tumors are usually subject to poor immunological control [63]. Encouragingly, inhibition of 
the PI3K-AKT-mTOR pathway using either a pan-PI3K inhibitor wortmannin, pan-AKT 
inhibitor, MK-2206 or mTOR inhibitor, rapamycin, has been demonstrated to reduce 
expression of PD-L1 within PTEN-mutant triple-negative breast cancer cell lines in vitro 
[60]. Loss of PTEN within preclinical melanoma models has been demonstrated to inhibit T 
cell-mediated tumor killing and to decrease CD8
+
 T cell infiltration within tumor tissue, 
which also correlated with poor outcomes to anticancer immunotherapies [53]. By contrast, it 
remains unlikely that inducible expression of PD-L1 by IFNs is regulated by the PI3K-AKT-
mTOR network. Indeed, patient-derived melanoma cell lines with wild type (WT) PTEN, 
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cultured in the presence of a PI3K inhibitors LY294002, BKM120, or with a dual inhibitor of 
both PI3K and mTOR, BEZ235, failed to attenuate PD-L1 expression level [64].  
 
Effects of PI3K-AKT-mTOR inhibitors on immune cells  
Within the tumor microenvironment, immune suppression can be mediated not only by tumor 
cell-intrinsic effects, but also via recruitment of regulatory immune cell subsets such as 
MDSCs and Tregs into the tumor [13, 65]. While inhibiting components of the PI3K-AKT-
mTOR pathway has been shown to reduce expression of immunosuppressive cytokines, 
chemokines, and checkpoint ligands, therapies such as these may also modulate the activity 
and viability of immunoregulatory cell types. For example, the differentiation of MDSCs 
appears to be heavily regulated by AKT; its inhibition has been demonstrated to limit MDSC 
differentiation in vitro. Nevertheless, the impact of AKT inhibition on MDSC differentiation 
within the tumor microenvironment remains poorly understood [66].  Additionally, it has 
been shown that a range of chemokines activate G-protein coupled receptors, tyrosine kinase, 
and toll-like receptors (TLRs) which signal via PI3Kγ (p110γ) within myeloid cells to 
promote their infiltration into tumor tissue [67]. Genetic and pharmacological inactivation of 
the p110γ was demonstrated to reduce α4β1 integrin-mediated adhesion of MDSCs and 
Tregs, limiting their infiltration and in turn reduced tumor growth and metastasis in murine 
models of melanoma, lung, pancreatic and breast cancers. Importantly, this reduction in 
tumor-associated inflammation and angiogenesis occurred without affecting systemic 
numbers of myeloid or lymphoid cells [67]. These data strongly support the findings of others 
who have demonstrated in pre-clinical models of colitis-associated cancer, mice lacking 
functional PI3Kγ (P110γ-/-) were found to harbour significantly fewer colon neoplasm in 
comparison to wild type controls [68, 69]. 
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Tregs have been understood for some time to limit the activity of anti-tumor immune 
responses via a number of mechanisms including the secretion of IL-10 and sequestration of 
IL-2 [70, 71]. Interestingly, several reports have demonstrated that the utilization of the 
PI3K-AKT-mTOR signaling pathway differs between regulatory and conventional T cells, 
such that inhibition might tip the scales away from immune suppression, in favour of anti-
tumour immunity [65, 72]. Using the pan-AKT inhibitors, IC87114, wortmannin, or MK-
2206, it has been shown that Tregs are preferentially susceptible to inhibition; enhancing the 
number of CD8
+
 T cells within tumor tissue, and improving tumor control [65]. To limit off-
target effects associated with pan-inhibitors, isoform specific inhibitors of PI3Kδ (p110δ) 
have also been developed and shown to effectively reduce tumor burden and metastasis in 
murine models of melanoma, lung, breast, and pancreatic cancers [73]. Specifically, P110δ 
inactivation in Tregs has been demonstrated to impair maintenance and function of Tregs in 
the periphery. Indeed, these cells produce less IL10, and express lower levels of CD38, 
despite maintenance of a Treg gene signature. Importantly, CD8
+
 T cell functions were 
preserved in the presence of this inhibitor [73]. Together, these data suggest that the PI3K-
AKT-mTOR pathway is critical for maintaining the immunosuppressive function of Tregs, 
however, its precise mechanism remains to be fully characterised. 
 
Following activation, CD8
+
 T cells differentiate into effectors that proliferate and produce 
effector cytokines. To meet this increased bioenergetics demands, these cells undergo 
metabolic re-programming from quiescent mitochondrial oxidative phosphorylation 
(OXPHOS) to glycolysis [74]. This switch to glycolysis is directly linked to increased 
effector functions and is thought to occur in response to T cell receptor (TCR)-mediated 
signaling via the PI3K-AKT-mTOR pathway [75]. Following a productive immune response 
which overtime results in a decline in cognate antigen, the conversion to memory T cells is 
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characterised by a shift back to mitochondrial OXPHOS, fuelled by fatty acid oxidation. 
Especially in the context of cancer, chronic TCR signaling can induce tumor-specific CD8
+
 T 
cell exhaustion. These cells upregulate PD1, which in vitro has been demonstrated to reduce 
PI3K-AKT-mTOR signaling which in turn results in decreased glycolysis [76]. Specifically, 
this occurred by repression of PPAR-gamma coactivator 1α (PGC1α) expression, which is 
essential for mitochondrial biogenesis and metabolic regulation. Within exhausted CD8
+
 T 
cells this then leads to a state of energetic insufficiency. Blockade of the PD1 pathway was 
shown to increase the energetic metabolism of effector T cells and to promote their effector 
functions [77]. Together, these data might suggest that inhibition of the AKT-PI3K-mTOR 
signaling pathway could have a deleterious effect on exhausted effector T cell function; 
however, this possibility has not been robustly explored. As such the optimal schedule of 
when to administer these inhibitors will have to be determined. Notwithstanding these 
observations, inhibition of this signaling pathway has been demonstrated to improve the 
development of memory CD8
+
 T cells with positive effects.   
 
Recently it was shown that the progression-free survival of melanoma patients treated with 
anti-PD-1 was heavily associated with the development and persistence of memory T cells 
[9]. Indeed, a key feature of checkpoint inhibitors given as monotherapy is their ability to 
induce durable responses in ~20-40% of patients treated with anti-CTLA-4 or anti-PD-1 
respectively [78, 79], in contrast with the immediate, but transient responses induced by 
conventional chemotherapy or by targeted therapies. The process of memory T cell 
differentiation appears to be influenced by a number of factors including collective input via 
the TCR, IL-2 and IL-12 receptors which feed signals into the PI3K-AKT-mTOR network 
[80]. Therefore a strong case can be made that AKT can govern the balance between terminal 
differentiation and the generation of CD8
+
 T cell memory. In fact, this notion has been 
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strongly supported by studies in which mTOR inhibition using rapamycin significantly 
strengthened both the quality and quantity of CD8
+
 T cells, enhancing memory T cell 
differentiation by promoting expansion of the memory precursor (KLRG1
-
CD127
+
) pool 
during the T-cell expansion phase, and accelerating memory T cell differentiation during the 
T-cell contraction phase [81]. Additionally, multiple studies have demonstrated in the context 
of cancer that inhibition of AKT can potently enhance memory T cell differentiation[82]. 
Mechanistically, it has been demonstrated that AKT can suppress the activity of memory-
promoting transcription factors such as FOXO and TCR/LEF/-catenin [83]. Inhibition 
therefore relieves this suppression and promotes memory differentiation. In the context of 
chronic antigen exposure, memory precursors have demonstrated a unique susceptibility to 
become exhausted, this perhaps provides a reason as to why T  cell memory development in 
the context of cancer, and in chronic infections can be stunted [84].  
 
Therapeutic combinations to improve anti-tumor immunity  
As single agent therapies, the efficacy of PI3K-AKT-mTOR inhibitors in the treatment of a 
variety of cancers has generally been underwhelming [12, 85]. There are several possible 
reasons as to why; most notably: i) administration of therapies at tolerated concentrations can 
fail to have biological and therapeutic efficacy; ii) these therapies are targeting a signaling 
pathway that is integral for the homeostasis of most tissues. For example, the PI3K-AKT-
mTOR pathway is important for patterning the development and activities of lymphocytes 
[86, 87]; a great deal of early preclinical work conducted within this field took advantage of 
in vitro systems, or immunodeficient animal models. While such analyses might have been 
useful for modelling the cytostatic features of PI3K-AKT-mTOR inhibitors, they are 
unfortunately not useful for dissecting potentially harmful immunocidal off-target effects. 
More recently, these potential effects have been taken into account and it was demonstrated 
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quite effectively that therapies targeting PI3Kγ, AKT, mTOR, or PI3Kδ were capable of 
augmenting tumor immune surveillance without broad toxicity [65, 67, 72, 81]. Tolerability 
notwithstanding, generally their efficacy within preclinical models remains modest. Given 
their immunomodulatory capacity, it is highly likely that the full potential of PI3K-AKT-
mTOR inhibitors could be best realized when used in combination therapies with either 
immunotherapies, or targeted therapies as discussed in the next section (Figure 3).  
 
Combination with immunotherapies 
It has been firmly established that the efficacy of cancer immunotherapies will depend on 
priming and generation of tumor neoantigen-specific T cells [88], that can migrate into tumor 
tissue [89], and mediate effector functions (to which tumor cells are sensitive) [62, 90], and 
develop stable immunological memory [9]. To achieve the most effective outcomes for 
patients treated with a variety of anti-cancer therapies, combination therapeutic strategies 
involving PI3K-AKT-mTOR inhibition may be of benefit (Figure 2) [1]. To enhance priming 
and activation of tumor antigen-specific T cells, various cancer vaccination strategies have 
been developed. These include more traditional approaches in which immunogenic, tumor-
specific peptides are combined with adjuvant and administered systemically, as well as more 
innovative strategies which involve the isolation of autologous DCs and loading them with 
tumor antigen ex vivo to be administered as a cellular vaccine [91, 92]. While such strategies 
are capable of generating systemic, tumor-specific T cell responses, their magnitude does not 
necessarily correlate with tumor regression. Mechanistically, this form of resistance has in 
some instances been demonstrated to occur as a result of T cell resistance. Upregulation of 
the PI3K-AKT-mTOR network can potently induce signaling via NF-кB, capable of driving 
transcription of a variety of anti-apoptotic molecules including cellular inhibitors of apoptosis 
(cIAPs), caspase-8/FADD (FAS-associated death domain)-like IL-1β-converting enzyme 
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(FLICE), inhibitory protein (c-FLIP) and members of the Bcl-2 family such as A1/BFL1 and 
BCL-XL [92, 93]. By therapeutically targeting up-stream PI3K-AKT signaling, sensitivity to 
tumor-specific CD8
+
 T cell-mediated cytotoxicity was shown to be enhanced [92]. These data 
suggest that the combination of peptide vaccine with PI3K-AKT inhibition would likely 
improve the sensitivity of tumors to immune-mediated assault (Figure 3). Broader 
characterisation might, however, be warranted to identify whether specific genetic variations 
were responsible for the upregulation in AKT which could be useful for predicting outcome.  
To enhance the effector function (migration, proliferation and cytotoxicity) of tumor-specific 
T cells, immunotherapies targeting the PD-1 and CTLA-4 immune checkpoints have 
demonstrated the greatest clinical benefit. The general consensus is that anti-CTLA4 therapy 
functions by promoting proliferation of tumor-specific CD8
+
 T cells within secondary 
lymphoid organs, while anti-PD1 therapy relieves exhaustion of tumor-specific CD8
+
 T cells 
within tumor tissue; enhancing the number and function of tumor-specific effectors [1]. Since 
their clinical inception, it has become apparent that therapies such as these are also often 
subject to primary or acquired resistance [94]. Our understanding of the mechanisms 
underlying resistance to these therapies is improving. Now, limited evidence suggests that 
defects in antigen presentation [88], T cell resistance [90], the secretion of 
immunosuppressive cytokines from tumor cells or immune cells, the presence and activity of 
MDSCs and Tregs within tumor tissue, and the failure to generate protective immunological 
memory can all contribute to failure to anti-cancer therapies [95]. As discussed, PI3K-AKT-
mTOR inhibition can augment the secretion of immunosuppressive cytokines [51-53], the 
infiltration of MDSCs and Tregs into tumor tissues [67-69], and promote the development of 
memory T cells [9, 96]. For these reasons, it is highly likely that the combining therapeutic 
strategies involving PI3K-AKT-mTOR inhibition with checkpoint blockade would be 
effective (Figure 3). Importantly however, several questions remain: i) would PI3K-AKT-
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mTOR inhibition complement anti-PD-1/anti-CTLA4 immunotherapies within resistant 
tumors in which β-catenin signaling is dysregulated? One study reported its dysregulation 
limited the chemotaxis of antigen presenting cells capable of priming tumor-specific 
immunity into tumor tissue [88], ii) it was recently shown that acquired resistance to anti-
PD1 therapy can occur as a result of T cell resistance to IFNγ (due to JAK 1 and 2 mutations) 
or due to defective presentation of cognate antigen (due to β2M mutations) [90]. iii) Would 
PI3K-AKT-mTOR inhibition be useful to sensitize tumors in which acquired resistance to 
anti-PD1 therapy has developed to alternative immunotherapies?  
 
Conceptual advances leading to the understanding that endogenous tumor-specific immune 
responses can be generated, prompted the development of immunotherapeutic strategies in 
which autologous T cells are isolated and expanded, or manipulated from patient ex vivo 
before reinfusion, to bolster tumor-specific immunity [97]. More traditional adoptive cell 
therapy (ACT) approaches involve the isolation of tumor-infiltrating lymphocytes (TILs) 
extracted from biopsy material [97]. One of the main features of TILs that has been 
associated with objective response is their long-term persistence after transfer. Unfortunately, 
TILs isolated from tumor material are usually terminally differentiated and unable to develop 
a memory phenotype [82, 98]. To overcome this limitation, AKT inhibition was shown in a 
mouse model of ACT, to reprogram the transcriptional profile of CD8
+
 T cells into that of 
memory cells. Functionally, this was shown to enhance their anti-tumor efficacy and to 
improve overall survival [82, 98].  More recently, ACT has been improved upon to allow for 
the ex vivo manipulation of CD8 T cells transduced with chimeric antigen receptor (CAR), 
specific for tumor antigens that are not restricted by MHC Class I (major histocompatibility 
complex I) [99]. While demonstrated to be effective in the treatment of a number of 
malignancies, the presence of IL-2 within ex vivo cultures, necessary to maintain viability, 
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has, paradoxically been shown to reduce CAR T cell activity [99]. Similarly, it was recently 
demonstrated that the efficacy of CAR T cells in the treatment of solid tumours in vivo, could 
be improved with the addition of PI3K inhibitors during ex vivo culturing, however, these 
were preliminary findings and the underlying mechanism remains to be fully elucidated [99, 
100].  
 
Combination with targeted therapies    
BRAF and MEK inhibitors have demonstrated broad efficacy in treatment of BRAF-mutant 
melanoma where tumor proliferation and survival is promoted by oncogenic activation. Like 
inhibitors of the PI3K-AKT-mTOR signaling pathway, the efficacy of these therapies have 
also been shown to depend on host-derived immunity in the form of CD8
+
 T cells and also 
NK cells; the infiltration of which into tumour tissue is enhanced following therapy [101]. 
Interestingly, the efficacy of these therapies is often limited due to the development of 
resistance [102]. A major mechanism by which resistance develops is via activation of the 
PI3K-AKT-mTOR pathway [102, 103]. The combination of therapies targeting BRAF/MEK 
and the PI3K-AKT-mTOR pathway have demonstrated additive or synergistic efficacy. For 
example, vemurafenib in combination with inhibitors of mTORCs 1 and 2 has been shown to 
be synergistic in the treatment of BRAF-mutant melanoma (Figure 3) [104-106]. In addition, 
the efficacy of therapies which inhibit epidermal growth factor receptor (EGFR) family 
member signaling such as erlotinib (which targets EGFR) and lapatinib (a dual inhibitor of 
EGFR and Her2) has also been shown in some cases to be limited by signaling via the PI3K-
AKT-mTOR network. Encouragingly, the combination of lapatinib with the AKT inhibitor 
MK-2206 has demonstrated efficacy in recent early phase clinical trials for treatment of 
various solid tumors [107]. 
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Conclusions  
The heterogeneity and adaptability of many tumors strongly supports the need to utilize 
robust therapies which target the disease on multiple fronts. Throughout this review, we have 
detailed how inhibition of components of the PI3K-AKT-mTOR network can have 
dichotomous functions; they can halt tumor cell proliferation, and augment tumor immune 
surveillance. The divergent responses to PI3K-AKT-mTOR inhibition to date have been 
caused by a variety of factors including cellular heterogeneity, dynamic interactions and 
cross-talk between different nodes of the PI3K-AKT-mTOR pathway, off-target effects upon 
immune cells and cellular plasticity. To release their broad potential, PI3K-AKT-mTOR 
inhibitors require further optimization of their dosage and scheduling with respect to their use 
in various combinations therapies. By defining the optimal approaches to combine PI3K-
AKT-mTOR inhibitors with other cancer therapies, particularly those targeting PD-1/PD-L1, 
it is hoped that the rates of both primary and acquired resistance could be reduced. It is 
probable that such therapeutic combinations could be associated with increased risk of 
inducing severe immune-related adverse events (irAEs). When used as single-agents, some 
PI3K inhibitors including idelalisib, are associated with what appear to be mild irAEs; this is 
seen with increased T cell infiltration within tissues, occurs more frequently within first-line 
patients who are more immunocompetent, and can be alleviated by administration of steroids 
[108]. Additionally, biallelic loss of PIK3CD within humans has been associated with similar 
symptoms, suggesting that these are likely to be irAEs. In fact, these effects are similar to 
irAEs observed in response to checkpoint blockade against PD-1and/or CTLA-4 [109]. 
Fortunately, such conditions are usually reversible following treatment withdrawal [109]. 
Moving forward, an increased understanding of the immuno-modulatory effects of PI3K-
AKT-mTOR inhibitors  may allow its rationale combination with other therapies to improve 
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clinical outcomes for patients although safety of each combination will have to be throughly 
assessed.  
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Figure Legends  
Figure 1. The PI3K-AKT-mTOR signaling network.  
The PI3Ks are family of 8 members, grouped into three classes. In the context of cancer, four 
class I enzymes, termed PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ appear to be of significance. These 
are heterodimers of a 110 kDa catalytic subunit (p110α, p110β, p110γ and p110δ) and a p85 
regulatory subunit. Activated adaptor proteins bind via YXXM motifs of PI3Ks and relieve 
p85-mediated inhibition of p110. This recruits p85-p110 heterodimers to their substrate, the 
lipid phosphatidylinositol-4,5-bisphosphate (PIP2), at the plasma membrane. PI3K (p110), 
then phosphorylate PIP2 to produce the second messenger phosphatidylinositol-3,4,5-
trisphosphate (PIP3). Phosphate and tensin homologue (PTEN), dephosphorylates PIP3 in 
position 3 inositol ring, thereby negatively regulating PI3K signaling outputs. Several 
pleckstrin homology (PH) domain-containing proteins, including SGK, PDK1 and most 
importantly, AKT, bind to PIP3 at the plasma membrane. The phosphorylation of AKT at 
Thr308 by PDK1 and at Ser473 by a complex involving mTOR/Rictor complex (mTORC2) 
results in full activation of this enzyme. AKT phosphorylates a host of cellular proteins 
including GSK3α, GSKβ, the FOXO transcription factors, MDM2, BAD, and p27KIP1 to 
facilitate survival and cell cycle entry. Additionally, AKT phosphorylates and inactivates 
Tuberin, a GTPase-activating protein (GAP) for the Ras homologue, Rheb. Inactivation of 
Tuberin allows GTP-bound Rheb to accumulate and activate the mTOR/Raptor complex 
(mTORC1), which ultimately regulates protein synthesis, RNA translation, cell growth, and 
autophagy. 
 
Figure 2. Suppressive mechanism mediated by the PI3K-AKT-mTOR network in the 
tumor microenvironment.A. Upregulation of AKT within tumor cells as a result of PTEN 
mutations, or other methods of abberant pathway activation can lead to the upregulation of 
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anti-apoptotic molecules and prevent tumor cells from undergoing apoptosis in response to 
CD8
+
 T cell-mediated assault. B. Additionally, some PTEN-mutant, and some PTEN wild 
type tumors with upregulated AKT signaling often secrete VEGF, a potent chemoattractant of 
MDSCs and Tregs. The presence of these cell types within tumor is negatively correlated 
with response to a variety of anti-cancer therapies; especially immunotherapies as they are 
capable of inhibiting the activity of a variety of immune cell types, particularly CD8
+
 T cells. 
C. PTEN-mutant tumours are often reported to constitutively express PD-L1, the ligand for 
the immune checkpoint receptor PD-1. The interaction of PD-L1 with PD-1 expressed on the 
surface of activated CD8
+
 T cells can induce a state of functional exhaustion and inhibit their 
anti-tumor activity. D. Immunosuppressive cytokines secreted from tumors as a result of 
PI3K-AKT-mTOR signaling can suppress tumor-specific CD8
+
 T cell activity (migration, 
proliferation and cytotoxicity). E. Together, these immunosuppressive effects can prevent the 
induction of protective immunological memory. Tem = effector memory, Tcm = central 
memory, Trm = tissue resident memory.  
 
Figure 3. Rationale for combining immunotherapies with PI3K-AKT-mTOR inhibitors. 
PI3K-AKT-mTOR (A) or BRAF/MEK (B) inhibitors can have both tumor cell-intrinsic and 
immune cell-intrinsic effects. By combining these targeted therapies with various 
immunotherapeutic approaches (C), it is likely that anti-tumor efficacy can be further 
improved. 
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TABLE 1 – PI3K/AKT/mTOR aberrations in main solid tumors* 
PI3K pathway 
aberrations 
Chromosome 
Location 
Protein Function Histopathology  
(Prevalence %) 
PIK3R1/2 
mutation  
PIK3R1 
(5q13.1) 
PIK3R2 
(19q13.2-
q13.4) 
Genes encoding p85α and 
p85β, the regulatory 
subunits of PI3K 
Prostate: 22% 
Endometrial Carcinoma: 20% 
(PIK3R1); 5% (PIK3R2) 
GBM: 8-10% 
Breast: 2% 
Colorectal: < 1% 
Skin SCC: 11% 
Melanoma 1-2% 
PIK3CA 
mutation 
3q26.3 Gene  encoding p110α, the 
catalytic subunit of PI3K 
Breast: 20%-50% 
Endometrial, ovarian: 25-
30% 
SCLC: 20-23% 
HNSCC: 20% 
Colorectal: 14% 
GBM: 10% 
Prostate: 6% 
NSCLC): 5% 
Melanoma 3% 
PIK3CA 
amplification 
3q26.3 Gene  encoding p110α, the 
catalytic subunit of PI3K 
NSCLC: 10-30% 
HNSCC: 20% 
Breast: 10% 
Esophageal SCC: 10% 
AKT1/2 
amplification 
AKT1 
14q32.32 
AKT2  
19q13.1-q13.2 
Genes encoding AKT1 
and 2 protein isoforms 
HNSCC: 5% 
Breast, ovarian, pancreatic, 
Gastric cancer: < 5% 
Colorectal cancer: < 1% 
34 
 
* PI3K-AKT-mTOR aberrations in haematopoietic malignancies is reviewed by Gao et al. 
[110] 
 
 
 
AKT1 mutation 14q32.32 Gene encoding for AKT1 
protein isoform 
Colorectal: 6% 
Breast (TNBC): 3% 
NSCLC: 1-2% 
Endometrial: 1% 
PTPN12 loss 7q11.23 Gene encoding the tumor 
suppressor PTPN12, a 
non-receptor tyrosine 
phosphatase leading to 
enhanced tyrosine 
phosphorylation of 
multiple growth factor 
receptors, that leads to 
PI3K pathway activation 
Breast: 23% 
Breast  (TNBC): 60% 
INPP4B loss 4q31.1 Gene encoding INPP4B,  
which dephosphorylates 
phosphatidylinositol 3,4-
bisphosphate (PI(3,4)P2) 
on the D4 position 
generating 
phosphatidylinositol 3-
phosphate (PI(3)P)  
Breast (TNBC): 30%-56% 
Lung (NSCLC): 47% 
Ovarian: 40% 
Prostate: 8% 
PTEN loss 10q23.3 Gene coding PTEN, that 
negatively regulates this 
pathway by 
dephosphorylating PIP3 at 
its D3 position, thereby 
inhibiting downstream 
kinase activation 
NSCLC: 75% 
Endometrial: 55% 
Ovarian: 45% 
Colorectal: 20%-40% 
Breast, HNSCC: 30% 
GBM: 60%-80% 
Prostate: 20% 
PTEN mutation 10q23.3 Gene coding PTEN, which 
negatively regulates this 
pathway by 
dephosphorylating PIP3 at 
its D3 position, thereby 
inhibiting downstream 
kinase activation 
Endometrial: 44% 
Breast: < 5% 
Colorectal: < 5% 
GBM: 5%-40% 
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TABLE 2 - PI3K/AKT/mTOR pathway inhibitors: clinical characteristics, genomic context and 
toxicity 
PI3K/AKT/mTOR 
pathway inhibitors  
Biomarkers of 
response 
Potential 
advantages 
Limitation Toxicity 
Dual PI3K/mTOR 
Inhibitors [111, 
112] 
Tumor types 
with loss-of-
function in the 
negative 
regulators 
PTEN, 
TSC1/2, and 
STK11 
Drugs with broadest 
activity profile 
Multikinase 
blockade leads 
to increased 
toxicity, this 
class of agents 
may not be as 
well suited to 
combination 
therapy as other 
agents 
Hyperglycemia, 
astenia, 
nausea/vomiting, 
diarrhea, rash, 
mucositis  
 
Isoform-Specific 
PI3K Inhibitors 
[113, 114] 
PIK3A 
mutation 
To be investigated in 
selective patients 
according to 
biomarkers of 
response 
Drugs with 
narrowest 
activity profile 
𝛼 – Hyperglycemia, 
astenia, 
nausea/vomiting, 
diarrhea  
𝛽 – Astenia, 
nausea/vomiting, 
diarrhea, anemia 
 
𝛿 – Astenia, 
nausea/vomiting, 
diarrhea, rash, liver 
dysfunction, 
pneumonitis, 
pyrexia, hematologic 
toxicities 
AKT inhibitors 
[115, 116] 
PTEN loss or 
PIK3CA 
mutations 
AKT inhibition 
counteracts its 
tumor-driven 
immunosuppressive 
effects through 
remodeling of the 
tumor 
microenvironment 
and restoring T cell 
metabolism. 
The response 
rate as single 
agent is 5% , 
hence 
combination is 
needed [85] 
Hyperglycemia, 
astenia, 
nausea/vomiting, 
diarrhea, rash  
mTORC1/2 
Inhibitors [117, 
118] 
Unknown mTORC1 and 
mTORC2 inhibition 
Genomic 
profiling of 
responsive 
tumors has not 
Hyperglycemia, 
astenia, 
nausea/vomiting, 
diarrhea, rash, 
pneumonitis, 
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been reported hepatoxicity 
Pan-class I PI3K 
inhibitors [119, 
120] 
Tumor types 
that lack 
PIK3CA 
mutations 
Better suited to 
combination therapy 
than dual 
PI3K/mTOR 
inhibitors 
The efficacy of pan-
PI3K inhibitors are 
not restricted to 
tumors harboring 
PIK3CA mutations 
Drugs with 
narrower 
activity profile 
than dual 
PI3K/mTORi 
Hyperglycemia, 
astenia, 
nausea/vomiting, 
diarrhea, rash 
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TABLE 3 – Current clinical trials investigating PI3K-AKT-mTOR inhibitors in solid 
tumors* 
Drug(s)(clinical 
trial number) 
Phase Histopathology Primary     
Endpoint(s) 
Secondary 
Endpoint(s) 
Monotherapy 
PI3K inibithors 
BYL719 
(NCT02145312) 
2 SCCHN DCR OR, PFS, OS, TTP, 
Toxicity, Safety, 
Quality of life 
BKM120 
(NCT01629615) 
2 Breast 
cancer 
Clinical benefit PFS, OS, AEs, Safety, 
PK 
BKM120 
(NCT01830504) 
2 Thyroid 
cancer 
PFS OR, OS, Safety 
BKM120 
(NCT01737450) 
2 Head and 
neck cancer 
DCR PFS, OS, Safety, OR, 
DOR, TTP 
BKM120 
(NCT01806649) 
2 Esophageal 
Squamous 
cell 
Carcinoma 
DCR Safety, PFS, OS 
CUDC-907 
(NCT02307240) 
1 NUT 
midline 
carcinoma 
Breast 
cancer 
Solid tumors 
MDT PK, Safety, Tolerability 
 
ZSTK474 
(NCT01682473) 
1 Solid tumors DLT PK 
BYl719 
(NCT02506556) 
 
2 Breast 
cancer 
OR CBR, PFS, Safety, 
Tolerability 
Lenvatinib 
(NCT02860936) 
2 Carcinomas 
of the 
Salivary 
Glands 
OR PFS, OS, Safety, 
Tolerability, DOR 
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PQR309 
(NCT02850744) 
2 Glioblastom
a multiforme 
PFS 
OR 
 
AEs, SAEs, Physical 
examination, 
Depression Test, PK, 
DOR 
BKM120 
(NCT02128724) 
1 NSCLC MTD Changes in 18F-
Misonidazole uptake as 
detected by PET-CT 
scans, PK 
AKT inhibitors 
ARQ 092 
(NCT01473095) 
1 Solid Tumors 
Malignant 
Lymphoma 
Safety 
Tolerability 
PK, PD, RP2D 
GSK2141795 
(NCT00920257) 
1 Solid Tumors 
Lymphoma 
RP2D Efficacy, 
Metabolite profile 
MK2206 
(NCT01283035) 
2 Ovarian cancer 
Fallopian 
cancer 
Peritoneal 
Cancer 
OR OS, PFS, Toxicity 
MK2206 
(NCT01277757) 
2 Breast cancer OR PFS, Median 
response duration, 
Safety 
MK2206 
(NCT01604772) 
2 Adenoid Cyst 
Carcinoma 
OR PFS, OS, Toxicity 
AZD5363 
(NCT02077569) 
2 Breast cancer PhD PK, Toxicity 
MK2206 
(NCT01349933) 
2 Head and neck 
cancer 
PFS 
OR 
AEs, OS, PFS 
GSK2110183 
(NCT01531894) 
2 Solid tumors 
Hematologic 
malignancies 
AEs 
PK 
Vital signs 
 
MK2206 
(NCT01260701) 
2 Gastric cancer 
Gastroesophage
al Junction 
OS PFS, OR, AEs 
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Cancer 
MK2206 
(NCT01425879) 
2 Biliary Cancer ORR AEs, OS, PFS 
MK2206 
(NCT01239355) 
2 Liver cancer PFS OR, OS 
 
MSC2363318A 
(NCT01971515) 
1 Solid tumors DLT PD, PK, BOR, 
CBR, AEs 
AZD5363 
(NCT01226316) 
1 Solid tumors Safety 
Tolerability 
PK, OR 
MK-2206 
(NCT01186705) 
2 Colorectal 
cancer 
ORR  
PQR 309 
(NCT02483858) 
1 Solid tumors Safety 
Tolerability 
DLT, PK 
Selumetinib 
(NCT00888134) 
2 Solid tumors OR in patients 
with cancer other 
than melanoma 
AKT Pathway 
activity, or in 
NSCLC and 
colon cancer, PFS 
mTOR inhibitors 
Everolimus 
(NCT01412515) 
2 Kaposi 
Sarcoma 
OR  
Everolimus 
(NCT01206764) 
4 Renal cell 
carcinoma 
PFS ORR, OR, Safety 
Everolimus or 
or Nilotinib 
Sorafenib or 
Lapatinib or 
Pazopanib  
(NCT02029001) 
2 Solid tumors 12-week PFS 
PFS 
OR, OS, Safety, 
Quality of life 
Combination therapy 
PI3K inhibitors 
Everolimus + 
Tamoxifen 
2 Breast cancer Clinical benefit at 
24 weeks 
Response, 
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(NC T01298713)  Toxicity, OS 
Everolimus + 
Octreotide LAR + 
Metformin 
(NCT02294006) 
2 pWDNETs PFS Safety, 
Tolerability, OS, 
OR 
BKM120 + Erlotinib 
(NCT01487265) 
2 NSCLC PFS DLT, OS, DOR, 
OR 
BKM120 + 
Cetuximab 
(NCT01816984) 
1/2 SCCHN Phosphorylated 
(p)-EGFR 
MTD 
Apoptosis 
induction, OR, 
OS, PFS,  
 
BYL719 + Letrozole 
(NCT01791478) 
1 Breast cancer MTD Clinical benefit, 
PFS, OS, OR,   
 
BYL719 + AUY922 
(NCT01613950) 
1 Gastric cancer DLT 
MTD 
AEs, BOR, PK, 
ORR, PFS, OS, 
SAEs 
GDC-0941 + 
Cisplatin 
(NCT01918306) 
1b/2 Breast cancer MTD 
OR 
CBR, TTP 
BKM120 + Cisplatin 
+ Etoposide 
(NCT02194049) 
1 Small cell lung 
cancer 
AEs MTD, OR, OS, 
TTP, PK 
WX-037 +/-  
WX-554 
(NCT01859351) 
1 Solid tumors DLT AEs, SAEs, PK 
Taselisib + 
Enzalutamide 
(NCT02457910) 
1/2 Breast cancer CBR 
MTD 
PFS, OR, PK 
BYL719 + Nab-
paclitaxel 
(NCT02379247) 
1/2 Breast cancer RP2D 
OR 
CBR, PK, PFS, 
OS 
Taselisib / Pictilisib 
+ Palbociclib  
(NCT02389842) 
1 Breast cancer RP2D 
Safety 
CBR 
PFS 
PK 
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DOR 
Taselisib / Pictilisib 
+ Palbociclib 
(NCT02389842) 
1 Solid tumors 
Breast cancer 
RP2D 
Safety 
Toxicity 
PK 
Copanlisib + 
Cetuximab 
(NCT02822482) 
1/2 SCCHN MTD 
RP2D 
OR, OS, AEs, PK 
GDC-0032 +  
Tamoxifen 
(NCT02285179) 
 
1 Breast cancer 
Ovarian cancer 
Uterine Cancer 
MDT Safety, PK, OR 
INC280 + Buparlisib 
(NCT01870726) 
1b/2 Glioblastoma PFS 
MTD 
SAEs, 
Tolerability, PK, 
OR, OS 
Letrozole +/- 
BYL719 or 
BKM120 
(NCT01923168) 
2 Breast cancer pCR 
OR 
AEs, PK 
BKM120 +  Weekly 
Cisplatin + 
Radiotherapy 
(NCT02113878) 
1 SCCHN MTD OR, TTP, OS 
AEB071 + BYL719 
(NCT02273219) 
1 Uveal Melanoma MTD AEs, PK, CBR, 
OS 
Copanlisib + 
Trastuzumab 
(NCT02705859) 
1 Breast cancer MTD 
CBR 
AEs/Toxicity, 
OS, PFS, DOR, 
Safety, 
Tolerability, TTP 
Fulvestrant +/- 
Alpelisib 
(NCT02437318) 
3 Breast cancer PFS OS, OR, Safety, 
Tolerability, PK, 
PFS 
BKM120/ Placebo + 
Fulvestrant 
(NCT01633060) 
3 Breast cancer PFS OS, OR, CBR, 
AEs, Overall 
health status 
BKM120 or 1 Ovarian cancer MTD Safety, PK 
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BYL719 + Olaparib 
(NCT01623349) 
Breast cancer RP2D  
Gedatolisib + 
Palbociclib + 
Faslodex 
(NCT02626507) 
1 Breast cancer Safety 
MTD 
pCR 
GSK2636771 + 
Paclitaxel 
(NCT02615730) 
1/2 Gastric cancer RP2D 
PFS 
DLT 
BKM120 + 
Tamoxifen 
(NCT02404844) 
2 Breast cancer PFS OS, OR, DCR, 
AEs, Incidence 
and severity of 
depressive 
episodes 
Taselisib/Placebo + 
Fulvestrant 
(NCT02340221) 
3 Breast cancer PFS OS, OR, AEs 
Gedatolisib + 
Paclitaxel + 
Carboplatin 
(NCT02920450) 
1/2 NSCLC DLT 
OR 
PFS, OS, AEs 
GSK2636771 + 
Enzalutamide 
(NCT02215096) 
 
1 
Prostate 
cancer 
AEs/SAEs 
DLT, Safety 
PK, Response 
Enzalutamide +/- 
LY3023414 
(NCT02407054) 
2 Prostate 
Cancer 
PFS TTP, PK, OR 
LEE011 +  BYL719 
+ Letrozole 
(NCT01872260) 
1/2 Breast cancer DLT Safety, 
AEs/SAEs, PK, 
OR, DOR, PFS 
PQR309+ Eribulin 
(NCT02723877) 
1/2 Breast cancer AEs/SAEs 
CBR 
OR 
TTR, DOR, PFS, 
TTP, PK, OS 
LEE011 + 
Fulvestrant + 
BYL719 or 
BKM120 
(NCT02088684) 
1/2 Breast cancer DLT 
PFS 
Safety, 
Tolerability, PK, 
OR, DOR, OS 
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INCB050465 + 
INCB039110 + 
Epacadostat 
(NCT02559492) 
1 Solid tumors DLT 
 
OR, PFS, DOR 
INCB050465 + 
Pembrolizumab 
(NCT02646748) 
1 Solid tumors Safety OR, PFS, DOR 
BKM120 + 
Trastuzumab + 
Paclitaxel 
(NCT01816594) 
2 Breast cancer pCR OR, pCR, Safety 
AKT inhibitors 
GSK2141795 + 
Dabrafenib + 
Trametinib 
(NCT01902173) 
1/2 Colon carcinoma 
Melanoma 
Ovarian cancer 
MTD OS, PFS, Toxicity 
MK2206 + 
Dinaciclib 
(NCT01783171) 
1 Pancreatic cancer MTD DCR, AEs, OS, 
PFS 
MK2206 + Lapatinib 
Ditosylate 
(NCT01281163) 
1 Breast cancer MTD Safety, PK, 
Response 
MK2206 + Lapatinib 
Ditosylate 
(NCT01245205) 
1 Breast cancer MTD 
AEs 
OR, PFS, DLT, 
PFS 
GSK1120212 + 
GSK2110183 
(NCT01476137) 
1 Solid tumors 
Myeloma 
 
Safety 
OR 
PK, PFS, DOR 
AZD5363 + 
Olaparib 
(NCT02338622) 
1 Solid tumors Safety 
MTD 
PK 
MK2206 + 
Selumetinib 
(NCT01519427) 
2 Melanoma OR Changes in 
Biomarker 
Expression, PFS, 
OS 
GSK2141795 + 
Trametinib 
2 Breast carcinoma OR CBR, DOR, AEs, 
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(NCT01964924) SAEs, PFS 
MK2206 + 
Selumetinib + 
Fluorouracil + 
Oxaliplatin 
(NCT01658943) 
2 Pancreatic cancer OS AEs, PFS, OR 
+/- GSK2141795 + 
Trametinib 
(NCT01979523) 
2 Uveal melanoma TTP Toxicity, OS, 
PFS, OR 
AZD5363 + 
Paclitaxel 
(NCT02423603) 
2 Breast cancer PFS  
MK-2206 + 
AZD6244 
(NCT01333475) 
2 Colorectal cancer pERK and pAKT 
Levels in Tumor 
Biopsies 
AEs 
Triciribine + 
Carboplatin 
(NCT01690468) 
1/2 Ovarian Cancer MTD OR, PFS, 
Duration of stable 
disease 
MK-2206 + 
Paclitaxel + 
Trastuzumab 
(NCT01235897) 
1 HER2-positive 
solid tumors 
MTD BOR 
ARQ 092 + 
carboplatin + 
paclitaxel 
or ARQ 092 + 
paclitaxel 
or ARQ 092 + 
anastrozole 
(NCT02476955) 
1 Solid tumors AEs PK, OR, DLT 
Afuresertib + 
Paclitaxel 
(NCT02240212) 
 
1 Gastric cancer SAEs 
Lab: ECG, LVEF, 
blood pressure, 
vital signs 
assessment 
PK, PFS, SAEs, 
AEs 
AZD5363 +/- 
docetaxel and 
prednisolone 
1/2 Prostate cancer DLT 
PFS 
Safety, 
Tolerability, PK, 
Biochemical OR 
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(NCT02121639) 
 
Paclitaxel +/- 
Ipatasertib 
(NCT02301988) 
2 Breast cancer pCR OR, Efficacy, 
Safety, PK 
Paclitaxel +/- 
Ipatasertib 
(NCT02162719) 
2 Breast cancer PFS OS, OR, DOR 
Ipatasertib + 
Cobimetinib 
(NCT01562275) 
1 Solid tumors DLT 
MTD 
PK, OR, DOR, 
PFS 
mTOR inhibitors 
Everolimus + 
Sorafenib 
(NCT01141309) 
2 Thyroid cancer OR PFS, Safety, 
Toxicity 
Temsirolimus + 
Sorafenib 
(NCT01025453) 
2 Thyroid Cancer OR PFS, Safety, 
Tolerability 
Paclitaxel followed 
by FEC or 
paclitaxel+RAD001 
followed by FEC 
(NCT00499603) 
2 Breast cancer Inhibition of PI3K 
pathway 
Response 
Temsirolimus + 
Letrozole or 
Letrozole 
(NCT00062751) 
2 Breast cancer OR BOR, TTP , PFS, 
DOR, Health 
Outcomes 
Assessment, 
Population with 
Response 
PF-05212384 + 
Docetaxel, Cisplatin 
or Dacomitinib 
(NCT01920061) 
1 Solid tumors DLT PK, Gene 
sequence data, 
OR 
Everolimus + 
Eribulin 
(NCT02616848) 
1 Breast cancer MTD PK, Safety 
mTOR inhibitors + AKT inhibitors 
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AZD2014 + 
AZD5363 + 
Olaparib 
(NCT02208375) 
 
1/2 Endometrial 
cancer 
Ovarian Cancer 
MTD OR 
Olaparib +/- 
AZD1775, 
AZD5363, or 
AZD2014 
(NCT02576444) 
2 Solid tumors OR  
mTOR inhibitors + PI3K inhibitors 
Alpelisib + 
Everolimus or 
Alpelisib+ 
Everolimus + 
Exemestane 
(NCT02077933) 
1 Breast cancer 
Renal cell cancer 
Pancreatic  
neuroendocrine 
tumors 
MTD 
DLT 
AEs 
Safety, 
Tolerability, PFS, 
DOR, CBR, OR, 
PFS 
MLN0128 + 
MLN1117 
(NCT01899053) 
1 Solid tumors Number of AEs 
PK 
OR, DOR 
*Source Document: Clinical Trial Gov. 2/10/2016. 
OR: Objective Response; SCCHN: Recurrent or Metastatic Squamous Cell Carcinoma of Head 
and Neck; NSCLC: Non small cell lung carcinoma; NUT: carcinomas characterized by 
chromosomal rearrangements that involve the gene encoding the nuclear protein of the testis 
(NUT); DCR: Disease control rate; PFS: Progression Free Survival; OS: Overall Survival; TTP: 
Time to progression; PK: Pharmacokinetics; PD: Pharmacodynamic;  pWDNETs: well-
differentiated neuroendocrine tumors; RR: Response rate; RP2D:  Recommended phase 2 trial 
dose; AEs: Adverse Events; MTD: Maximum Tolerated Dose; DOR: Duration of response; 
DLT: Dose-limiting toxicity; OR: Overall response; BOR: Best Overall Response; SAEs: 
Serious Adverse Events; CBR: Clinical Benefit Rate; TTP: Time to disease progression; pCR: 
Pathological complete response; ECOG: Eastern Cooperative Oncology Group; PS: 
Performance status; ECG: Electrocardiogram; LEVF: Left ventricular ejection fraction; FEC: 5-
Fluorouracil + Epirubicin + Cyclophosphamide  
 
 



